Abstract
Tobacco carcinogen treatment of immortalized human bronchial epithelial (HBE) cells has uncovered novel targets for cancer chemoprevention. Experiments were conducted with HBE cells and independent treatments with tobacco carcinogens along with the chemopreventive agent all-trans-retinoic acid (RA). That work highlighted D-type and E-type cyclins as novel molecular pharmacologic targets of several chemopreventive agents. G1 cyclins are often aberrantly expressed in bronchial preneoplasia and lung cancers. This implicated these species as targets for clinical cancer chemoprevention. Retinoid regulation mechanisms of D-type cyclins in lung cancer chemoprevention have been comprehensively explored. Retinoid chemoprevention has been mechanistically linked to proteasomal degradation of cyclin D1 and cyclin D3. Threonine 286 mutation stabilized cyclin D1, implicating phosphorylation in this retinoid chemoprevention. Studies with a phospho-specific anti-cyclin D1 antibody confirmed this hypothesis. Glycogen synthase kinase (GSK) inhibitors established a role for this kinase in the retinoid regulation of cyclin D1, but not cyclin D3. Involvement of D-type cyclins in this chemoprevention was shown using small interfering RNAs (siRNAs). Gene profiling experiments highlighted the E1-like ubiquitin-activating enzyme (UBE1L) in the retinoid regulation of cyclin D1. Proof of principle trials have translated these studies into the clinic and established that chemopreventive agents can target D-type cyclins. These findings have been built upon with a targeted combination regimen that cooperatively affects D-type cyclins. Taken together, these preclinical and clinical findings strongly implicate these cyclins as novel molecular pharmacological targets for cancer chemoprevention.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Betticher DC, Heighway J, Hasleton PS, Altermatt HJ, Ryder WD, Cerny T, Thatcher N (1996) Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer 73:294–300
Betticher DC, White GR, Vonlanthen S, Liu X, Kappeler A, Altermatt HJ, Thatcher N, Heighway J (1997) G1 control gene status is frequently altered in resectable non-small cell lung cancer. Int J Cancer 74:556–562
Boyle JO, Langenfeld J, Lonardo F, Sekula D, Reczek P, Rusch V, Dawson MI, Dmitrovsky E (1999) Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells. J Natl Cancer Inst 91:373–379
Dmitrovsky E, Sporn MB (2002) Pharmacology of cancer chemoprevention. In: Bertino JB (ed) Encyclopedia of cancer. Academic, San Diego, pp 449–456
Dragnev KH, Petty WJ, Dmitrovsky E (2003a) Retinoid targets for cancer therapy and prevention. Cancer Biol Ther 2:S150–S156
Dragnev KH, Petty WJ, Dmitrovsky E (2003b) Targeted combination lung cancer therapy with a non-classical retinoid and an EGFR inhibitor. Proc AACR, 44:617
Dragnev KH, Stover D, Dmitrovsky E (2003c) Lung cancer prevention: the guidelines. Chest 123:60S–71S
Dragnev KH, Pitha-Rowe I, Ma Y, Petty WJ, Sekula D, Murphy B, Rendi M, Suh N, Desai NB, Sporn MB, Freemantle SJ, Dmitrovsky E (2004) Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. Clin Cancer Res 10:2570–2577
Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, Memoli V, Rigas JR, Dmitrovsky E (2005) Bexarotene and erlotinib for aerodigestive tract cancer. J Clin Oncol 23:8757–8764
Fan B, Negro-Vilar A, Lamph WW, Bissonnette RP (2004) A retinoid X receptor (RXR)-selective agonist bexarotene produces synergistic growth inhibitory activity with gefitinib in non-small cell lung cancer (NSCLC) cell lines. Proc ASCO 23:652
Hayashi H, Ogawa N, Ishiwa N, Yazawa T, Inayama Y, Ito T, Kitamura H (2001) High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients. Lung Cancer 34:59–65
Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T (2001) Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410:1111–1116
Kitareewan S, Pitha-Rowe I, Sekula D, Lowrey CH, Nemeth MJ, Golub TR, Freemantle SJ, Dmitrovsky E (2002) UBE1L is a retinoid target that triggers PML/RARα degradation and apoptosis in acute promyelocytic leukemia. Proc Natl Acad Sci U S A 99:3806–3811
Kok K, Hofstra R, Pilz A, van den Berg A, Terpstra P, Buys CH, Carritt B (1993) A gene in the chromosomal region 3p21 with greatly reduced expression in lung cancer is similar to the gene for ubiquitin-activating enzyme. Proc Natl Acad Sci U S A 90:6071–6075
Langenfeld J, Lonardo F, Kiyokawa H, Passalaris T, Ahn MJ, Rusch V, Dmitrovsky E (1996) Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation. Oncogene 13:1983–1990
Langenfeld J, Kiyokawa H, Sekula D, Boyle J, Dmitrovsky E (1997) Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc Natl Acad Sci U S A 94:12070–12074
Loeb KR, Haas AL (1992) The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. J Biol Chem 267:7806–7813
Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E, Klimstra DS (1999) Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res 59:2470–2476
Lonardo F, Dragnev KH, Freemantle SJ, Ma Y, Memoli N, Sekula D, Knauth EA, Beebe JS, Dmitrovsky E (2002) Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res 8:54–60
Ma Y, Feng Q, Sekula D, Diehl JA, Freemantle SJ, Dmitrovsky E (2005) Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms. Cancer Res 65:6476–6483
Mate JL, Ariza A, Aracil C, Lopez D, Isamat M, Perez-Piteira J, Navas-Palacios JJ (1996) Cyclin D1 overexpression in non-small cell lung carcinoma: correlation with Ki67 labeling index and poor cytoplasmic differentiation. J Pathol 180:395–399
Mendelsohn J (2001) The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 8:3–9
Moon RC, Mehta RG, Rao KVN (1994) Retinoids and cancer in experimental animals. In: Sporn MB, Roberts AB, Goodman DS (eds) The retinoids: biology, chemistry, and medicine, 2nd edn. Raven Press, New York, pp 573–595
Narasimhan J, Potter JL, Haas AL (1996) Conjugation of the 15-kDa interferon-induced ubiquitin homolog is distinct from that of ubiquitin. J Biol Chem 271:324–330
Papadimitrakopoulou VA, Izzo J, Mao L, Keck J, Hamilton D, Shin DM, El-Naggar A, den Hollander P, Liu D, Hittelman WN, Hong WK (2001) Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clin Cancer Res 7:3127–3134
Petty WJ, Dragnev KH, Memoli VA, Ma Y, Desai NB, Biddle A, Davis TH, Nugent WC, Memoli N, Hamilton M, Iwata KK, Rigas JR, Dmitrovsky E (2004) Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin Cancer Res 10:7547–7554
Petty WJ, Li N, Biddle A, Bounds R, Nitkin C, Ma Y, Dragnev KH, Freemantle SJ, Dmitrovsky E (2005) A novel retinoic acid receptor ? isoform and retinoid resistance in lung carcinogenesis. J Natl Cancer Inst 97:1645–1651
Pickart CM (2001a) Mechanisms underlying ubiquitination. Ann Rev Biochem 70:503–533
Pickart CM (2001b) Ubiquitin enters the new millennium. Mol Cell 8:499–504
Pitha-Rowe I, Hassel BA, Dmitrovsky E (2004a) Involvement of UBE1L in ISG15 conjugation during retinoid-induced differentiation of acute promyelocytic leukemia. J Biol Chem 279:18178–18187
Pitha-Rowe I, Petty WJ, Feng Q, Koza-Taylor PH, Dimattia DA, Pinder L, Dragnev KH, Memoli N, Memoli V, Turi T, Beebe J, Kitareewan S, Dmitrovsky E (2004b) Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention. Cancer Res 64:8109–8115
Ratschiller D, Heighway J, Gugger M, Kappeler A, Pirnia F, Schmid RA, Borner MM, Betticher DC (2003) Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol 21:2085–2093
Rigas JR, Dragnev KH, Petty WJ, Nugent WC, Memoli VA, Black CC, Lewis LD, Loewen G, Negro-Vilar A, Dmitrovsky E (2005) A proof-of-principle trial of bexarotene in patients (pts) with resectable non-small cell lung cancer (NSCLC). Proc Am Soc Clin Onc 23:654s
Rusch V, Klimstra D, Linkov I, Dmitrovsky E (1995) Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res 55:1365–1372
Rusch V, Mendelsohn J, Dmitrovsky E (1996) The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev 7:133–141
Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232
Schauer IE, Siriwardana S, Langan TA, Sclafani RA (1994) Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci U S A 91:7827–7831
Sporn MB, Dunlop NM, Newton DL, Smith JM (1976) Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35:1332–1338
Tamayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, Dmitrovsky E, Lander ES, Golub TR (1999) Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci U S A 96:2907–2912
Vonlanthen S, Heighway J, Kappeler A, Altermatt HJ, Borner MM, Betticher DC (2000) p21 is associated with cyclin D1, p16INK4a and pRb expression in resectable non-small cell lung cancer. Int J Oncol 16:951–957
Weston A, Harris CC (1997) Chemical carcinogenesis. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR (eds) Cancer medicine, 4th edn., Vol. 1, Williams and Wilkins, Baltimore, pp 261–276
Witschi H, Espiritu I, Suffia M, Pinkerton KE (2002) Expression of cyclin D1/2 in the lungs of strain A/J mice fed chemopreventive agents. Carcinogenesis 23:289–294
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Dragnev, K.H. et al. (2007). Uncovering Novel Targets for Cancer Chemoprevention. In: Senn, HJ., Kapp, U. (eds) Cancer Prevention. Recent Results in Cancer Research, vol 174. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-37696-5_21
Download citation
DOI: https://doi.org/10.1007/978-3-540-37696-5_21
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-37695-8
Online ISBN: 978-3-540-37696-5
eBook Packages: MedicineMedicine (R0)